Deka Bank Deutsche Girozentrale Biocryst Pharmaceuticals Inc Transaction History

Deka Bank Deutsche Girozentrale

$54.1 Billion
Q4 2024

A detailed history of Deka Bank Deutsche Girozentrale transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Deka Bank Deutsche Girozentrale holds 73,765 shares of BCRX stock, worth $663,147. This represents 0.0% of its overall portfolio holdings.

Number of Shares

73,765

Previous 73,765 -0.0%

Holding current value

$663,147

Previous $557,000 0.54%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 28, 2022	BUY	$11.56 - $19.76 $77,452 - $132,392	6,700 Added 9.99%	73,765 $1.21 Million
Q4 2021 Feb 02, 2022	BUY	$11.18 - $15.46 $20,124 - $27,828	1,800 Added 2.76%	67,065 $894,000
Q1 2021 Apr 28, 2021	SELL	$7.37 - $13.61 $294,800 - $544,400	-40,000 Reduced 38.0%	65,265 $643,000
Q4 2020 Mar 12, 2021	SELL	$3.37 - $8.61 $252,750 - $645,750	-75,000 Reduced 41.61%	105,265 $734,000
Q3 2020 Oct 29, 2020	BUY	$3.43 - $5.53 $618,308 - $996,865	180,265 New	180,265 $711,000
Q4 2019 Feb 04, 2020	SELL	$1.59 - $3.45 $50,085 - $108,675	-31,500 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$2.5 - $3.73 $78,750 - $117,495	-31,500 Reduced 50.0%	31,500 $100,000
Q2 2019 Aug 01, 2019	BUY	$2.91 - $9.15 $71,295 - $224,175	24,500 Added 63.64%	63,000 $229,000
Q1 2019 May 10, 2019	BUY	$7.38 - $9.72 $51,660 - $68,040	7,000 Added 22.22%	38,500 $276,000
Q4 2018 Feb 12, 2019	SELL	$6.51 - $9.6 $45,570 - $67,200	-7,000 Reduced 18.18%	31,500 $251,000
Q3 2018 Nov 09, 2018	SELL	$5.52 - $7.99 $5,520 - $7,990	-1,000 Reduced 2.53%	38,500 $0
Q1 2018 May 03, 2018	BUY	$4.35 - $5.82 $171,825 - $229,890	39,500 New	39,500 $189,000

Others Institutions Holding BCRX

# of Institutions

285

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.67B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.

Account

Deka Bank Deutsche Girozentrale Biocryst Pharmaceuticals Inc Transaction History